search

Active clinical trials for "Mycoses"

Results 161-170 of 546

Anidulafungin PK in Infants and Toddlers

Invasive Fungal Infections

This is a prospective, open-label, single center, pharmacokinetic study of anidulafungin in infants and toddlers less than 24 months of age with suspected serious infection. There will be up to 24 subjects enrolled; each will receive anidulafungin. Patients will receive anidulafungin 3 mg/kg loading dose on day 1 of study and will receive 1.5 mg/kg every 24 hours on study days 2-5.Plasma pharmacokinetics will be evaluated using a limited sampling scheme. We hypothesize that the PK parameters of anidulafungin will not differ from those observed in older children and adults.

Completed8 enrollment criteria

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Adult Grade III Lymphomatoid GranulomatosisAnaplastic Large Cell Lymphoma60 more

This phase I trial is studying the side effects and best dose of PXD101 and bortezomib in treating patients with advanced solid tumors or lymphomas. PXD101 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PXD101 may also cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving PXD101 together with bortezomib may kill more cancer cells.

Completed42 enrollment criteria

Antifungal Use in Oncohematological Neutropenic Patients

Invader Fungal Infection

Primary purpose: Frequency of use of broad-spectrum antifungals in the episode of neutropenia. Secondary purposes:To determine the safety and toxicity measure by: Frequency of Invader Fungal Infection. Frequency of global use of broad-spectrum antifungals as amphotericine, itraconazole, voriconazole, caspofungin, terbinafine, during the period of study. Mortality Development of nephrotoxicity Use of galactomannan in this clinical context Time of administration of empirical antifungal therapy of broad-spectrum.

Completed22 enrollment criteria

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem...

Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in Remission66 more

This phase II trial studies how well cyclophosphamide works in preventing chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients with hematological malignancies. Giving chemotherapy and total-body irradiation before transplantation helps stop the growth of cancer cells and prevents the patient's immune system from rejecting the donor's stem cells. Healthy stem cells from a donor that are infused into the patient help the patient's bone marrow make blood cells; red blood cells, white blood cells, and platelets. Sometimes, however, the transplanted donor cells can cause an immune response against the body's normal cells, which is called graft-versus-host disease (GVHD). Giving cyclophosphamide after transplant may prevent this from happening or may make chronic GVHD less severe.

Completed37 enrollment criteria

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia...

Adult Acute Lymphoblastic LeukemiaAdult Acute Myeloid Leukemia38 more

This randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia. Giving cefepime hydrochloride over a longer period of time may be more effective than giving cefepime hydrochloride over the standard time.

Completed10 enrollment criteria

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and MycosesAppendicitis3 more

The purpose of this study is to compare the clinical response rates of doripenem versus a comparator antibiotic in treatment of hospitalized patients with complicated intra-abdominal infections.

Completed4 enrollment criteria

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma,...

Cutaneous T Cell LymphomaMycosis Fungoides

The study objective is to demonstrate that the UVADEX® Sterile Solution formulation of methoxsalen used in conjunction with the UVAR XTS Photopheresis System can have a clinical effect on the skin manifestations of CTCL (mycosis fungoides) in early stage disease.

Completed34 enrollment criteria

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma49 more

This phase I trial is studying the side effects and best dose of 17-DMAG in treating patients with metastatic or unresectable solid tumors or lymphomas. Drugs used in chemotherapy, such as 17-DMAG, work in different ways to stop cancer cells from dividing so they stop growing or die

Completed45 enrollment criteria

Interleukin-2 in Treating Patients With Mycosis Fungoides

Lymphoma

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides.

Completed72 enrollment criteria

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

LymphomaT-Cell2 more

The purpose of this study is to determine the response rate of patients with T-cell malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin (Accutane).

Completed14 enrollment criteria
1...161718...55

Need Help? Contact our team!


We'll reach out to this number within 24 hrs